Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Why should I use sharewise

Magforce AG Stock

Price
Target price
€3.19

€3.19

4.780%
0.14
4.780%
€9.15

€9.15

 
Latest predictions
€8.00
28.10.19
buy
€10.30
21.03.19
buy
Your prediction

Magforce AG Stock

Magforce AG dominated the market today, gaining €0.14 (4.780%).
With 0 Sell predictions and 2 Buy predictions the community sentiment towards the Magforce AG stock is not clear.
With a target price of €9.00 there is potential for a 182.132% increase which would mean more than doubling the current price of €3.19 for Magforce AG.
Register To Post

Other discussions about Magforce AG Stock

New thread

News

DGAP-News: MagForce AG Publishes Shareholder Letter

DGAP-News: MagForce AG Publishes Shareholder Letter

DGAP-News: MagForce AG: MagForce USA, Inc. has received FDA Approval to proceed with its Streamlined Trial Protocol for the next Stage of Pivotal U.S. Single-Arm Study for the Focal Ablation of Intermediate Risk Prostate Cancer with the NanoTherm The

DGAP-News: MagForce AG: MagForce USA, Inc. has received FDA Approval to proceed with its Streamlined Trial Protocol for the next Stage of Pivotal U.S. Single-Arm Study for the Focal Ablation of Intermediate Risk Prostate Cancer with the NanoTherm The

DGAP-Adhoc: MagForce AG: MagForce USA, Inc. has received FDA Approval to proceed with its Streamlined Trial Protocol for the next Stage of Pivotal U.S. Single-Arm Study for the Focal Ablation of Intermediate Risk Prostate Cancer with the NanoTherm Th

DGAP-Adhoc: MagForce AG: MagForce USA, Inc. has received FDA Approval to proceed with its Streamlined Trial Protocol for the next Stage of Pivotal U.S. Single-Arm Study for the Focal Ablation of Intermediate Risk Prostate Cancer with the NanoTherm Th

DGAP-News: MagForce AG and Hufeland Klinikum GmbH Announce Cooperation Agreement and Opening of a New NanoTherm Treatment Center in Thuringia, Germany

DGAP-News: MagForce AG and Hufeland Klinikum GmbH Announce Cooperation Agreement and Opening of a New NanoTherm Treatment Center in Thuringia, Germany

DGAP-News: MagForce AG announces successful capital increase of the subsidiary MagForce USA, Inc.

DGAP-News: MagForce AG announces successful capital increase of the subsidiary MagForce USA, Inc.

MagForce AG: 'NanoTherm School' successfully enters its second round with Module B

MagForce AG: 'NanoTherm School' successfully enters its second round with Module B

DGAP-News: New hope for brain tumor patients in Saxony: Paracelsus Clinic Zwickau and MagForce AG open new NanoTherm therapy center for the East German region

DGAP-News: New hope for brain tumor patients in Saxony: Paracelsus Clinic Zwickau and MagForce AG open new NanoTherm therapy center for the East German region